這項前瞻性臨床試驗評估採用第三代TKI olverembatinib、雙特異性CD3/CD19 T細胞銜接器 blinatumomab 及BCL-2選擇性抑制劑 venetoclax 的「輕化療」方案，用於新確診兒童／青少年Ph+ ALL患者的療效與安全性。與CCCG-ALL-2020方案相比，CCCG-Ph+ B-ALL-2025方案將作以下修改
適應症：Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)、Childhood Leukemia, Acute Lymphoblastic
收案條件
納入條件
- Must meet all items below:
- Age older than 1 month to younger 18 years.
- Newly diagnosed Philadelphia chromosome-positive or BCR::ABL1-positive B-ALL.
- Written informed consent of the parents or other legally authorized guardian of the patient according to local law and regulations.
排除條件
- Should be excluded if had any item below:
- ALL evolved from CML.
- Known underlying congenital immunodeficiency or metabolic disease.
- Congenital heart disease with cardiac insufficiency.
- Gastrointestinal dysfunction or gastrointestinal diseases that may significantly alter the absorption of study drug.
- Severe malnutrition, uncontrolled active infections, or serious cardiovascular diseases.
- Subjects with significant CNS disorder (e.g., uncontrolled seizure disorder, autoimmune disease involving CNS).
- Treated with glucocorticoids for ≥14 days, or targeted inhibitor for \> 7 days within one month before enrollment, or any chemotherapy or any systemic anticancer therapy (including but not limited to any TKI) or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression).
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。